SC
GCVRZ

Sculptor Capital’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Sculptor Capital’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-11,930,969
Closed -$24.1M – 853
2013
Q3 		$24.1M Sell
11,930,969
-3,360
-0% -$6.4K 0.07% 321
2013
Q2 		$22.7M Buy
+11,934,329
New +$21M 0.07% 306

Other funds holding GCVRZ

FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $19.6B AUM 25.25% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Sculptor Capital's GCVRZ Position: Q4 2013 in Review

Sculptor Capital sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2013, closing a stake of 11,930,969 shares — an estimated $24.1M sold.

Sculptor Capital first reported a position in GCVRZ in Q2 2013 and held it in 2 quarters. The position peaked at $24.1M in Q3 2013. 130 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2013.

  • Sculptor Capital reported no remaining Sanofi Contingent Value Rights position as of Q4 2013 after selling out during the quarter.
  • Sculptor Capital sold 11,930,969 Sanofi Contingent Value Rights shares in Q4 2013, an estimated $24.1M.
  • Sculptor Capital first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 2 quarters.
  • Sculptor Capital's Sanofi Contingent Value Rights position peaked at $24.1M in Q3 2013.
  • 130 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2013.

Based on Sculptor Capital's 13F filing for Q4 2013, filed 14 Feb 2014.